At Week 22, both groups had a high expression of TTF1; three OI fetuses had 39%, 60%, and 45% of TTF1 expression, respectively, whereas the control fetuses had 70% and 100% of expression (Table S1). This evidence concerns the gene TTF1 and osteogenesis imperfecta.